Work

The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.7_suppl.187

Authors: Johann Sebastian De Bono, Carmel Jo Pezaro, Silke Gillessen, Neal D. Shore, Luke T. Nordquist, Eleni Efstathiou, John C. Araujo, William R. Berry, Glenn Liu, Nicholas J. Vogelzang, Aurelius Gabriel Omlin, Robert J. Schotzinger, Joel Robert Eisner, William R. Moore

Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, Kantonsspital St. Gallen, Carolina Urologic Research Center, Urology Cancer Center and GU Research Network, National and Kapodistrian University of Athens, Alexandra Hospital, The University of Texas MD Anderson Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Comprehensive Cancer Centers of Nevada, Viamet Pharmaceuticals (United States), Innocrin Pharmaceuticals (United States)

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1822147457

Cites:

Cited by: 11

Related to: 10